End: Jan 17, 2019
Re-irradiation with SBRT for Pancreatic Cancer
January 16th at 5pm PST /January 17th at 9am China Standard Time
Professor Zhang Huojun, MD, PhD
Professor and Chairman of Radiation Oncology Department, Chairman of CyberKnife Center, Changhai Hospital, China
Prof. Zhang specializes in malignant tumor (pancreatic tumor, primary liver cancer, liver metastasis, lung cancer, renal cancer, prostate cancer as well as colon/rectum cancer) treatment with CyberKnife, SBRT and interventional radiology.
To develop a predictive model for stratification of patients with pancreatic cancer who may achieve survival benefits from re-irradiation with stereotactic body radiation therapy (SBRT).
The score was developed based on clinical predictors of OS in 31 patients receiving two courses of SBRT with Cox proportional hazards model. Results were then validated in another cohort with 11 participants to assess the performance of the score.
In the training cohort, the median BED10 of the first and second SBRT was 59.5 Gy (48–85.5 Gy) and 50.2 Gy (43.7–66.9 Gy) in 5–8 fractions, while in the validation cohort, the median BED10 of the first and second SBRT was 59.5 Gy (52.5–66.9 Gy) and 47.7 Gy (40.6–54.8 Gy) in 5–8 fractions. The interval between the first and second SBRT of the training cohort and validation cohort was 10.5 months (6.1–24.3 months) and 12.8 months (6.5–29.1 months), respectively. Multivariable analysis showed that tumor stage (P = 0.005), BED10 (P = 0.006) and CA19-9 response (P = 0.04) were significantly predictive of overall survival, which formed SCAD score (named after the initials of factors). Patients with the score < 3 points had a superior OS compared with those with the score ≥ 3 points in the validation cohort (median OS has not been reached vs. 15.9 months, P = 0.032).
The SCAD score may have the potential to identify individuals benefiting from re-SBRT and be a step toward more personalized medicine.